Orchard Therapeutics plc
Orchard Therapeutics plc ORTX Peers
See (ORTX) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ORTX | $16.70 | +0.30% | 380.11M | -4.07 | -$4.10 | N/A |
| VRTX | $434.38 | +3.14% | 111.55B | -114.31 | -$3.80 | N/A |
| REGN | $584.99 | +2.39% | 62.10B | 14.87 | $39.33 | +0.15% |
| SGEN | $228.74 | -0.07% | 43.15B | -57.19 | -$4.00 | N/A |
| ALNY | $283.40 | +5.92% | 36.95B | -135.60 | -$2.09 | N/A |
| ARGX | $561.75 | +5.54% | 34.30B | 34.27 | $16.39 | N/A |
| BNTX | $92.34 | +0.28% | 22.20B | -25.79 | -$3.58 | N/A |
| BGNE | $184.71 | +0.49% | 20.21B | -22.55 | -$8.19 | N/A |
| DNA-WT | $0.27 | -2.76% | 18.73B | N/A | N/A | N/A |
| RPRX | $33.12 | +2.57% | 18.62B | 13.52 | $2.45 | +2.58% |
Stock Comparison
ORTX vs VRTX Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, VRTX has a market cap of 111.55B. Regarding current trading prices, ORTX is priced at $16.70, while VRTX trades at $434.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas VRTX's P/E ratio is -114.31. In terms of profitability, ORTX's ROE is -0.50%, compared to VRTX's ROE of -0.06%. Regarding short-term risk, ORTX is less volatile compared to VRTX. This indicates potentially lower risk in terms of short-term price fluctuations for ORTX.
ORTX vs REGN Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, REGN has a market cap of 62.10B. Regarding current trading prices, ORTX is priced at $16.70, while REGN trades at $584.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas REGN's P/E ratio is 14.87. In terms of profitability, ORTX's ROE is -0.50%, compared to REGN's ROE of +0.15%. Regarding short-term risk, ORTX is less volatile compared to REGN. This indicates potentially lower risk in terms of short-term price fluctuations for ORTX.
ORTX vs SGEN Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, SGEN has a market cap of 43.15B. Regarding current trading prices, ORTX is priced at $16.70, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas SGEN's P/E ratio is -57.19. In terms of profitability, ORTX's ROE is -0.50%, compared to SGEN's ROE of -0.17%. Regarding short-term risk, ORTX is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for ORTX.
ORTX vs ALNY Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, ALNY has a market cap of 36.95B. Regarding current trading prices, ORTX is priced at $16.70, while ALNY trades at $283.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas ALNY's P/E ratio is -135.60. In terms of profitability, ORTX's ROE is -0.50%, compared to ALNY's ROE of -5.09%. Regarding short-term risk, ORTX is less volatile compared to ALNY. This indicates potentially lower risk in terms of short-term price fluctuations for ORTX.
ORTX vs ARGX Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, ARGX has a market cap of 34.30B. Regarding current trading prices, ORTX is priced at $16.70, while ARGX trades at $561.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas ARGX's P/E ratio is 34.27. In terms of profitability, ORTX's ROE is -0.50%, compared to ARGX's ROE of +0.16%. Regarding short-term risk, ORTX is less volatile compared to ARGX. This indicates potentially lower risk in terms of short-term price fluctuations for ORTX.
ORTX vs BNTX Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, BNTX has a market cap of 22.20B. Regarding current trading prices, ORTX is priced at $16.70, while BNTX trades at $92.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas BNTX's P/E ratio is -25.79. In terms of profitability, ORTX's ROE is -0.50%, compared to BNTX's ROE of -0.03%. Regarding short-term risk, ORTX is less volatile compared to BNTX. This indicates potentially lower risk in terms of short-term price fluctuations for ORTX.
ORTX vs BGNE Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, BGNE has a market cap of 20.21B. Regarding current trading prices, ORTX is priced at $16.70, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas BGNE's P/E ratio is -22.55. In terms of profitability, ORTX's ROE is -0.50%, compared to BGNE's ROE of -0.12%. Regarding short-term risk, ORTX is less volatile compared to BGNE. This indicates potentially lower risk in terms of short-term price fluctuations for ORTX.
ORTX vs DNA-WT Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, DNA-WT has a market cap of 18.73B. Regarding current trading prices, ORTX is priced at $16.70, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, ORTX's ROE is -0.50%, compared to DNA-WT's ROE of -0.63%. Regarding short-term risk, ORTX is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for ORTX.
ORTX vs RPRX Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, RPRX has a market cap of 18.62B. Regarding current trading prices, ORTX is priced at $16.70, while RPRX trades at $33.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas RPRX's P/E ratio is 13.52. In terms of profitability, ORTX's ROE is -0.50%, compared to RPRX's ROE of +0.16%. Regarding short-term risk, ORTX is less volatile compared to RPRX. This indicates potentially lower risk in terms of short-term price fluctuations for ORTX.
ORTX vs SMMT Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, SMMT has a market cap of 16.78B. Regarding current trading prices, ORTX is priced at $16.70, while SMMT trades at $22.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas SMMT's P/E ratio is -66.91. In terms of profitability, ORTX's ROE is -0.50%, compared to SMMT's ROE of -0.70%. Regarding short-term risk, ORTX is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for ORTX.
ORTX vs UTHR Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, UTHR has a market cap of 13.71B. Regarding current trading prices, ORTX is priced at $16.70, while UTHR trades at $303.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas UTHR's P/E ratio is 12.10. In terms of profitability, ORTX's ROE is -0.50%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, ORTX is less volatile compared to UTHR. This indicates potentially lower risk in terms of short-term price fluctuations for ORTX.
ORTX vs EXEL Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, EXEL has a market cap of 12.62B. Regarding current trading prices, ORTX is priced at $16.70, while EXEL trades at $46.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas EXEL's P/E ratio is 26.28. In terms of profitability, ORTX's ROE is -0.50%, compared to EXEL's ROE of +0.24%. Regarding short-term risk, ORTX is less volatile compared to EXEL. This indicates potentially lower risk in terms of short-term price fluctuations for ORTX.
ORTX vs KRTX Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, KRTX has a market cap of 12.60B. Regarding current trading prices, ORTX is priced at $16.70, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas KRTX's P/E ratio is -28.09. In terms of profitability, ORTX's ROE is -0.50%, compared to KRTX's ROE of -0.25%. Regarding short-term risk, ORTX is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for ORTX.
ORTX vs GMAB Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, GMAB has a market cap of 12.40B. Regarding current trading prices, ORTX is priced at $16.70, while GMAB trades at $19.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas GMAB's P/E ratio is 11.56. In terms of profitability, ORTX's ROE is -0.50%, compared to GMAB's ROE of +0.24%. Regarding short-term risk, ORTX is less volatile compared to GMAB. This indicates potentially lower risk in terms of short-term price fluctuations for ORTX.
ORTX vs INCY Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, INCY has a market cap of 12.15B. Regarding current trading prices, ORTX is priced at $16.70, while INCY trades at $62.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas INCY's P/E ratio is 313.80. In terms of profitability, ORTX's ROE is -0.50%, compared to INCY's ROE of +0.01%. Regarding short-term risk, ORTX is less volatile compared to INCY. This indicates potentially lower risk in terms of short-term price fluctuations for ORTX.
ORTX vs BMRN Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, BMRN has a market cap of 11.17B. Regarding current trading prices, ORTX is priced at $16.70, while BMRN trades at $58.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas BMRN's P/E ratio is 21.58. In terms of profitability, ORTX's ROE is -0.50%, compared to BMRN's ROE of +0.09%. Regarding short-term risk, ORTX is less volatile compared to BMRN. This indicates potentially lower risk in terms of short-term price fluctuations for ORTX.
ORTX vs RXDX Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, RXDX has a market cap of 9.56B. Regarding current trading prices, ORTX is priced at $16.70, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas RXDX's P/E ratio is -56.47. In terms of profitability, ORTX's ROE is -0.50%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, ORTX is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for ORTX.
ORTX vs ASND Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, ASND has a market cap of 9.51B. Regarding current trading prices, ORTX is priced at $16.70, while ASND trades at $157.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas ASND's P/E ratio is -21.09. In terms of profitability, ORTX's ROE is -0.50%, compared to ASND's ROE of +1.91%. Regarding short-term risk, ORTX is less volatile compared to ASND. This indicates potentially lower risk in terms of short-term price fluctuations for ORTX.
ORTX vs MRNA Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, MRNA has a market cap of 9.15B. Regarding current trading prices, ORTX is priced at $16.70, while MRNA trades at $23.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas MRNA's P/E ratio is -2.71. In terms of profitability, ORTX's ROE is -0.50%, compared to MRNA's ROE of -0.30%. Regarding short-term risk, ORTX is less volatile compared to MRNA. This indicates potentially lower risk in terms of short-term price fluctuations for ORTX.
ORTX vs IMGN Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, IMGN has a market cap of 8.73B. Regarding current trading prices, ORTX is priced at $16.70, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas IMGN's P/E ratio is -111.55. In terms of profitability, ORTX's ROE is -0.50%, compared to IMGN's ROE of +0.05%. Regarding short-term risk, ORTX is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for ORTX.
ORTX vs CERE Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, CERE has a market cap of 8.19B. Regarding current trading prices, ORTX is priced at $16.70, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas CERE's P/E ratio is -16.47. In terms of profitability, ORTX's ROE is -0.50%, compared to CERE's ROE of -0.99%. Regarding short-term risk, ORTX is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for ORTX.
ORTX vs ROIVW Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, ROIVW has a market cap of 7.83B. Regarding current trading prices, ORTX is priced at $16.70, while ROIVW trades at $2.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas ROIVW's P/E ratio is -0.67. In terms of profitability, ORTX's ROE is -0.50%, compared to ROIVW's ROE of -0.02%. Regarding short-term risk, ORTX is less volatile compared to ROIVW. This indicates potentially lower risk in terms of short-term price fluctuations for ORTX.
ORTX vs CORT Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, CORT has a market cap of 7.78B. Regarding current trading prices, ORTX is priced at $16.70, while CORT trades at $73.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas CORT's P/E ratio is 63.79. In terms of profitability, ORTX's ROE is -0.50%, compared to CORT's ROE of +0.20%. Regarding short-term risk, ORTX is less volatile compared to CORT. This indicates potentially lower risk in terms of short-term price fluctuations for ORTX.
ORTX vs ROIV Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, ROIV has a market cap of 7.68B. Regarding current trading prices, ORTX is priced at $16.70, while ROIV trades at $10.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas ROIV's P/E ratio is -10.76. In terms of profitability, ORTX's ROE is -0.50%, compared to ROIV's ROE of -0.02%. Regarding short-term risk, ORTX is less volatile compared to ROIV. This indicates potentially lower risk in terms of short-term price fluctuations for ORTX.
ORTX vs TECH Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, TECH has a market cap of 7.56B. Regarding current trading prices, ORTX is priced at $16.70, while TECH trades at $48.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas TECH's P/E ratio is 58.12. In terms of profitability, ORTX's ROE is -0.50%, compared to TECH's ROE of +0.06%. Regarding short-term risk, ORTX is less volatile compared to TECH. This indicates potentially lower risk in terms of short-term price fluctuations for ORTX.
ORTX vs RVMD Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, RVMD has a market cap of 7.35B. Regarding current trading prices, ORTX is priced at $16.70, while RVMD trades at $39.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas RVMD's P/E ratio is -9.84. In terms of profitability, ORTX's ROE is -0.50%, compared to RVMD's ROE of -0.37%. Regarding short-term risk, ORTX is less volatile compared to RVMD. This indicates potentially lower risk in terms of short-term price fluctuations for ORTX.
ORTX vs RETA Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, RETA has a market cap of 6.57B. Regarding current trading prices, ORTX is priced at $16.70, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas RETA's P/E ratio is -66.29. In terms of profitability, ORTX's ROE is -0.50%, compared to RETA's ROE of +0.47%. Regarding short-term risk, ORTX is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for ORTX.
ORTX vs JAZZ Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, JAZZ has a market cap of 6.54B. Regarding current trading prices, ORTX is priced at $16.70, while JAZZ trades at $106.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas JAZZ's P/E ratio is 14.41. In terms of profitability, ORTX's ROE is -0.50%, compared to JAZZ's ROE of +0.12%. Regarding short-term risk, ORTX is less volatile compared to JAZZ. This indicates potentially lower risk in terms of short-term price fluctuations for ORTX.
ORTX vs MDGL Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, MDGL has a market cap of 6.48B. Regarding current trading prices, ORTX is priced at $16.70, while MDGL trades at $291.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas MDGL's P/E ratio is -16.35. In terms of profitability, ORTX's ROE is -0.50%, compared to MDGL's ROE of -0.51%. Regarding short-term risk, ORTX is less volatile compared to MDGL. This indicates potentially lower risk in terms of short-term price fluctuations for ORTX.
ORTX vs BPMC Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, BPMC has a market cap of 6.43B. Regarding current trading prices, ORTX is priced at $16.70, while BPMC trades at $99.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas BPMC's P/E ratio is -39.64. In terms of profitability, ORTX's ROE is -0.50%, compared to BPMC's ROE of -0.49%. Regarding short-term risk, ORTX is less volatile compared to BPMC. This indicates potentially lower risk in terms of short-term price fluctuations for ORTX.
ORTX vs BBIO Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, BBIO has a market cap of 6.41B. Regarding current trading prices, ORTX is priced at $16.70, while BBIO trades at $33.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas BBIO's P/E ratio is -9.48. In terms of profitability, ORTX's ROE is -0.50%, compared to BBIO's ROE of +0.49%. Regarding short-term risk, ORTX is less volatile compared to BBIO. This indicates potentially lower risk in terms of short-term price fluctuations for ORTX.
ORTX vs HALO Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, HALO has a market cap of 6.03B. Regarding current trading prices, ORTX is priced at $16.70, while HALO trades at $48.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas HALO's P/E ratio is 13.02. In terms of profitability, ORTX's ROE is -0.50%, compared to HALO's ROE of +1.22%. Regarding short-term risk, ORTX is less volatile compared to HALO. This indicates potentially lower risk in terms of short-term price fluctuations for ORTX.
ORTX vs VRNA Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, VRNA has a market cap of 5.91B. Regarding current trading prices, ORTX is priced at $16.70, while VRNA trades at $69.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas VRNA's P/E ratio is -34.76. In terms of profitability, ORTX's ROE is -0.50%, compared to VRNA's ROE of -0.90%. Regarding short-term risk, ORTX is less volatile compared to VRNA. This indicates potentially lower risk in terms of short-term price fluctuations for ORTX.
ORTX vs ABCM Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, ABCM has a market cap of 5.52B. Regarding current trading prices, ORTX is priced at $16.70, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, ORTX's ROE is -0.50%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, ORTX is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for ORTX.
ORTX vs ISEE Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, ISEE has a market cap of 5.51B. Regarding current trading prices, ORTX is priced at $16.70, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas ISEE's P/E ratio is -22.44. In terms of profitability, ORTX's ROE is -0.50%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, ORTX is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for ORTX.
ORTX vs TLX Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, TLX has a market cap of 5.44B. Regarding current trading prices, ORTX is priced at $16.70, while TLX trades at $16.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas TLX's P/E ratio is 180.56. In terms of profitability, ORTX's ROE is -0.50%, compared to TLX's ROE of +0.14%. Regarding short-term risk, ORTX is less volatile compared to TLX. This indicates potentially lower risk in terms of short-term price fluctuations for ORTX.
ORTX vs TGTX Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, TGTX has a market cap of 5.33B. Regarding current trading prices, ORTX is priced at $16.70, while TGTX trades at $33.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas TGTX's P/E ratio is 134.36. In terms of profitability, ORTX's ROE is -0.50%, compared to TGTX's ROE of +0.19%. Regarding short-term risk, ORTX is less volatile compared to TGTX. This indicates potentially lower risk in terms of short-term price fluctuations for ORTX.
ORTX vs AXSM Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, AXSM has a market cap of 5.28B. Regarding current trading prices, ORTX is priced at $16.70, while AXSM trades at $107.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas AXSM's P/E ratio is -18.58. In terms of profitability, ORTX's ROE is -0.50%, compared to AXSM's ROE of -3.64%. Regarding short-term risk, ORTX is less volatile compared to AXSM. This indicates potentially lower risk in terms of short-term price fluctuations for ORTX.
ORTX vs IONS Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, IONS has a market cap of 5.25B. Regarding current trading prices, ORTX is priced at $16.70, while IONS trades at $32.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas IONS's P/E ratio is -11.03. In terms of profitability, ORTX's ROE is -0.50%, compared to IONS's ROE of -0.00%. Regarding short-term risk, ORTX is less volatile compared to IONS. This indicates potentially lower risk in terms of short-term price fluctuations for ORTX.
ORTX vs ALKS Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, ALKS has a market cap of 5.15B. Regarding current trading prices, ORTX is priced at $16.70, while ALKS trades at $31.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas ALKS's P/E ratio is 14.86. In terms of profitability, ORTX's ROE is -0.50%, compared to ALKS's ROE of +0.25%. Regarding short-term risk, ORTX is less volatile compared to ALKS. This indicates potentially lower risk in terms of short-term price fluctuations for ORTX.
ORTX vs NUVL Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, NUVL has a market cap of 5.10B. Regarding current trading prices, ORTX is priced at $16.70, while NUVL trades at $71.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas NUVL's P/E ratio is -16.06. In terms of profitability, ORTX's ROE is -0.50%, compared to NUVL's ROE of -0.31%. Regarding short-term risk, ORTX is less volatile compared to NUVL. This indicates potentially lower risk in terms of short-term price fluctuations for ORTX.
ORTX vs ADMA Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, ADMA has a market cap of 4.58B. Regarding current trading prices, ORTX is priced at $16.70, while ADMA trades at $19.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas ADMA's P/E ratio is 22.86. In terms of profitability, ORTX's ROE is -0.50%, compared to ADMA's ROE of +0.72%. Regarding short-term risk, ORTX is less volatile compared to ADMA. This indicates potentially lower risk in terms of short-term price fluctuations for ORTX.
ORTX vs ALPN Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, ALPN has a market cap of 4.46B. Regarding current trading prices, ORTX is priced at $16.70, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas ALPN's P/E ratio is -101.52. In terms of profitability, ORTX's ROE is -0.50%, compared to ALPN's ROE of -0.15%. Regarding short-term risk, ORTX is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for ORTX.
ORTX vs OPT Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, OPT has a market cap of 4.20B. Regarding current trading prices, ORTX is priced at $16.70, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas OPT's P/E ratio is -1.52. In terms of profitability, ORTX's ROE is -0.50%, compared to OPT's ROE of +2.60%. Regarding short-term risk, ORTX is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for ORTX.
ORTX vs MRTX Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, MRTX has a market cap of 4.12B. Regarding current trading prices, ORTX is priced at $16.70, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas MRTX's P/E ratio is -4.82. In terms of profitability, ORTX's ROE is -0.50%, compared to MRTX's ROE of -0.40%. Regarding short-term risk, ORTX is less volatile compared to MRTX. This indicates potentially lower risk in terms of short-term price fluctuations for ORTX.
ORTX vs PCVX Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, PCVX has a market cap of 3.99B. Regarding current trading prices, ORTX is priced at $16.70, while PCVX trades at $30.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas PCVX's P/E ratio is -7.74. In terms of profitability, ORTX's ROE is -0.50%, compared to PCVX's ROE of -0.17%. Regarding short-term risk, ORTX is less volatile compared to PCVX. This indicates potentially lower risk in terms of short-term price fluctuations for ORTX.
ORTX vs RYTM Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, RYTM has a market cap of 3.84B. Regarding current trading prices, ORTX is priced at $16.70, while RYTM trades at $60.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas RYTM's P/E ratio is -21.54. In terms of profitability, ORTX's ROE is -0.50%, compared to RYTM's ROE of -1.80%. Regarding short-term risk, ORTX is less volatile compared to RYTM. This indicates potentially lower risk in terms of short-term price fluctuations for ORTX.
ORTX vs KRYS Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, KRYS has a market cap of 3.77B. Regarding current trading prices, ORTX is priced at $16.70, while KRYS trades at $130.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas KRYS's P/E ratio is 31.25. In terms of profitability, ORTX's ROE is -0.50%, compared to KRYS's ROE of +0.14%. Regarding short-term risk, ORTX is less volatile compared to KRYS. This indicates potentially lower risk in terms of short-term price fluctuations for ORTX.
ORTX vs RYZB Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, RYZB has a market cap of 3.75B. Regarding current trading prices, ORTX is priced at $16.70, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas RYZB's P/E ratio is -57.86. In terms of profitability, ORTX's ROE is -0.50%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, ORTX is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for ORTX.
ORTX vs CBAY Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, CBAY has a market cap of 3.73B. Regarding current trading prices, ORTX is priced at $16.70, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas CBAY's P/E ratio is -32.81. In terms of profitability, ORTX's ROE is -0.50%, compared to CBAY's ROE of -0.32%. Regarding short-term risk, ORTX is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for ORTX.
ORTX vs PTCT Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, PTCT has a market cap of 3.59B. Regarding current trading prices, ORTX is priced at $16.70, while PTCT trades at $45.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas PTCT's P/E ratio is 6.96. In terms of profitability, ORTX's ROE is -0.50%, compared to PTCT's ROE of -0.72%. Regarding short-term risk, ORTX is less volatile compared to PTCT. This indicates potentially lower risk in terms of short-term price fluctuations for ORTX.
ORTX vs CYTK Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, CYTK has a market cap of 3.56B. Regarding current trading prices, ORTX is priced at $16.70, while CYTK trades at $29.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas CYTK's P/E ratio is -5.64. In terms of profitability, ORTX's ROE is -0.50%, compared to CYTK's ROE of +8.01%. Regarding short-term risk, ORTX is less volatile compared to CYTK. This indicates potentially lower risk in terms of short-term price fluctuations for ORTX.
ORTX vs RNA Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, RNA has a market cap of 3.49B. Regarding current trading prices, ORTX is priced at $16.70, while RNA trades at $28.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas RNA's P/E ratio is -9.66. In terms of profitability, ORTX's ROE is -0.50%, compared to RNA's ROE of -0.27%. Regarding short-term risk, ORTX is less volatile compared to RNA. This indicates potentially lower risk in terms of short-term price fluctuations for ORTX.
ORTX vs SWTX Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, SWTX has a market cap of 3.47B. Regarding current trading prices, ORTX is priced at $16.70, while SWTX trades at $46.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas SWTX's P/E ratio is -13.51. In terms of profitability, ORTX's ROE is -0.50%, compared to SWTX's ROE of -0.51%. Regarding short-term risk, ORTX is less volatile compared to SWTX. This indicates potentially lower risk in terms of short-term price fluctuations for ORTX.
ORTX vs SRPT Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, SRPT has a market cap of 3.47B. Regarding current trading prices, ORTX is priced at $16.70, while SRPT trades at $35.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas SRPT's P/E ratio is -13.36. In terms of profitability, ORTX's ROE is -0.50%, compared to SRPT's ROE of -0.20%. Regarding short-term risk, ORTX is less volatile compared to SRPT. This indicates potentially lower risk in terms of short-term price fluctuations for ORTX.
ORTX vs RARE Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, RARE has a market cap of 3.29B. Regarding current trading prices, ORTX is priced at $16.70, while RARE trades at $34.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas RARE's P/E ratio is -5.98. In terms of profitability, ORTX's ROE is -0.50%, compared to RARE's ROE of -1.86%. Regarding short-term risk, ORTX is less volatile compared to RARE. This indicates potentially lower risk in terms of short-term price fluctuations for ORTX.
ORTX vs ACLX Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, ACLX has a market cap of 3.22B. Regarding current trading prices, ORTX is priced at $16.70, while ACLX trades at $58.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas ACLX's P/E ratio is -19.55. In terms of profitability, ORTX's ROE is -0.50%, compared to ACLX's ROE of -0.35%. Regarding short-term risk, ORTX is less volatile compared to ACLX. This indicates potentially lower risk in terms of short-term price fluctuations for ORTX.
ORTX vs SLNO Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, SLNO has a market cap of 3.21B. Regarding current trading prices, ORTX is priced at $16.70, while SLNO trades at $69.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas SLNO's P/E ratio is -15.97. In terms of profitability, ORTX's ROE is -0.50%, compared to SLNO's ROE of -0.78%. Regarding short-term risk, ORTX is less volatile compared to SLNO. This indicates potentially lower risk in terms of short-term price fluctuations for ORTX.
ORTX vs AKRO Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, AKRO has a market cap of 3.19B. Regarding current trading prices, ORTX is priced at $16.70, while AKRO trades at $39.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas AKRO's P/E ratio is -10.66. In terms of profitability, ORTX's ROE is -0.50%, compared to AKRO's ROE of -0.32%. Regarding short-term risk, ORTX is less volatile compared to AKRO. This indicates potentially lower risk in terms of short-term price fluctuations for ORTX.
ORTX vs CRSP Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, CRSP has a market cap of 3.14B. Regarding current trading prices, ORTX is priced at $16.70, while CRSP trades at $36.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas CRSP's P/E ratio is -8.09. In terms of profitability, ORTX's ROE is -0.50%, compared to CRSP's ROE of -0.20%. Regarding short-term risk, ORTX is less volatile compared to CRSP. This indicates potentially lower risk in terms of short-term price fluctuations for ORTX.
ORTX vs VKTX Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, VKTX has a market cap of 3.08B. Regarding current trading prices, ORTX is priced at $16.70, while VKTX trades at $27.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas VKTX's P/E ratio is -23.62. In terms of profitability, ORTX's ROE is -0.50%, compared to VKTX's ROE of -0.14%. Regarding short-term risk, ORTX is less volatile compared to VKTX. This indicates potentially lower risk in terms of short-term price fluctuations for ORTX.
ORTX vs ACAD Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, ACAD has a market cap of 2.95B. Regarding current trading prices, ORTX is priced at $16.70, while ACAD trades at $17.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas ACAD's P/E ratio is 12.85. In terms of profitability, ORTX's ROE is -0.50%, compared to ACAD's ROE of +0.35%. Regarding short-term risk, ORTX is less volatile compared to ACAD. This indicates potentially lower risk in terms of short-term price fluctuations for ORTX.
ORTX vs SRRK Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, SRRK has a market cap of 2.92B. Regarding current trading prices, ORTX is priced at $16.70, while SRRK trades at $30.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas SRRK's P/E ratio is -12.48. In terms of profitability, ORTX's ROE is -0.50%, compared to SRRK's ROE of -1.29%. Regarding short-term risk, ORTX is less volatile compared to SRRK. This indicates potentially lower risk in terms of short-term price fluctuations for ORTX.
ORTX vs CRNX Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, CRNX has a market cap of 2.92B. Regarding current trading prices, ORTX is priced at $16.70, while CRNX trades at $31.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas CRNX's P/E ratio is -8.21. In terms of profitability, ORTX's ROE is -0.50%, compared to CRNX's ROE of -0.31%. Regarding short-term risk, ORTX is less volatile compared to CRNX. This indicates potentially lower risk in terms of short-term price fluctuations for ORTX.
ORTX vs CPRX Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, CPRX has a market cap of 2.90B. Regarding current trading prices, ORTX is priced at $16.70, while CPRX trades at $23.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas CPRX's P/E ratio is 15.15. In terms of profitability, ORTX's ROE is -0.50%, compared to CPRX's ROE of +0.28%. Regarding short-term risk, ORTX is less volatile compared to CPRX. This indicates potentially lower risk in terms of short-term price fluctuations for ORTX.
ORTX vs MORF Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, MORF has a market cap of 2.86B. Regarding current trading prices, ORTX is priced at $16.70, while MORF trades at $56.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas MORF's P/E ratio is -14.88. In terms of profitability, ORTX's ROE is -0.50%, compared to MORF's ROE of -0.27%. Regarding short-term risk, ORTX is more volatile compared to MORF. This indicates potentially higher risk in terms of short-term price fluctuations for ORTX.
ORTX vs MOR Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, MOR has a market cap of 2.86B. Regarding current trading prices, ORTX is priced at $16.70, while MOR trades at $18.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas MOR's P/E ratio is -12.64. In terms of profitability, ORTX's ROE is -0.50%, compared to MOR's ROE of +7.43%. Regarding short-term risk, ORTX is less volatile compared to MOR. This indicates potentially lower risk in terms of short-term price fluctuations for ORTX.
ORTX vs MRUS Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, MRUS has a market cap of 2.77B. Regarding current trading prices, ORTX is priced at $16.70, while MRUS trades at $40.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas MRUS's P/E ratio is -9.63. In terms of profitability, ORTX's ROE is -0.50%, compared to MRUS's ROE of -0.41%. Regarding short-term risk, ORTX is less volatile compared to MRUS. This indicates potentially lower risk in terms of short-term price fluctuations for ORTX.
ORTX vs PTGX Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, PTGX has a market cap of 2.75B. Regarding current trading prices, ORTX is priced at $16.70, while PTGX trades at $44.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas PTGX's P/E ratio is 56.94. In terms of profitability, ORTX's ROE is -0.50%, compared to PTGX's ROE of +0.09%. Regarding short-term risk, ORTX is less volatile compared to PTGX. This indicates potentially lower risk in terms of short-term price fluctuations for ORTX.
ORTX vs KDNY Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, KDNY has a market cap of 2.71B. Regarding current trading prices, ORTX is priced at $16.70, while KDNY trades at $40.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas KDNY's P/E ratio is -12.47. In terms of profitability, ORTX's ROE is -0.50%, compared to KDNY's ROE of -0.41%. Regarding short-term risk, ORTX is less volatile compared to KDNY. This indicates potentially lower risk in terms of short-term price fluctuations for ORTX.
ORTX vs MTSR Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, MTSR has a market cap of 2.69B. Regarding current trading prices, ORTX is priced at $16.70, while MTSR trades at $25.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas MTSR's P/E ratio is -12.62. In terms of profitability, ORTX's ROE is -0.50%, compared to MTSR's ROE of -0.55%. Regarding short-term risk, ORTX is less volatile compared to MTSR. This indicates potentially lower risk in terms of short-term price fluctuations for ORTX.
ORTX vs MYOV Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, MYOV has a market cap of 2.62B. Regarding current trading prices, ORTX is priced at $16.70, while MYOV trades at $26.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas MYOV's P/E ratio is -14.05. In terms of profitability, ORTX's ROE is -0.50%, compared to MYOV's ROE of +0.50%. Regarding short-term risk, ORTX is more volatile compared to MYOV. This indicates potentially higher risk in terms of short-term price fluctuations for ORTX.
ORTX vs LEGN Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, LEGN has a market cap of 2.55B. Regarding current trading prices, ORTX is priced at $16.70, while LEGN trades at $27.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas LEGN's P/E ratio is -23.47. In terms of profitability, ORTX's ROE is -0.50%, compared to LEGN's ROE of -0.16%. Regarding short-term risk, ORTX is less volatile compared to LEGN. This indicates potentially lower risk in terms of short-term price fluctuations for ORTX.
ORTX vs APGE Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, APGE has a market cap of 2.42B. Regarding current trading prices, ORTX is priced at $16.70, while APGE trades at $40.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas APGE's P/E ratio is -11.23. In terms of profitability, ORTX's ROE is -0.50%, compared to APGE's ROE of -0.19%. Regarding short-term risk, ORTX is less volatile compared to APGE. This indicates potentially lower risk in terms of short-term price fluctuations for ORTX.
ORTX vs MLTX Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, MLTX has a market cap of 2.39B. Regarding current trading prices, ORTX is priced at $16.70, while MLTX trades at $37.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas MLTX's P/E ratio is -19.93. In terms of profitability, ORTX's ROE is -0.50%, compared to MLTX's ROE of -0.00%. Regarding short-term risk, ORTX is less volatile compared to MLTX. This indicates potentially lower risk in terms of short-term price fluctuations for ORTX.
ORTX vs PRVB Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, PRVB has a market cap of 2.38B. Regarding current trading prices, ORTX is priced at $16.70, while PRVB trades at $24.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas PRVB's P/E ratio is -16.43. In terms of profitability, ORTX's ROE is -0.50%, compared to PRVB's ROE of +1.33%. Regarding short-term risk, ORTX is more volatile compared to PRVB. This indicates potentially higher risk in terms of short-term price fluctuations for ORTX.
ORTX vs IMVT Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, IMVT has a market cap of 2.36B. Regarding current trading prices, ORTX is priced at $16.70, while IMVT trades at $13.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas IMVT's P/E ratio is -5.31. In terms of profitability, ORTX's ROE is -0.50%, compared to IMVT's ROE of -0.78%. Regarding short-term risk, ORTX is less volatile compared to IMVT. This indicates potentially lower risk in terms of short-term price fluctuations for ORTX.
ORTX vs IBRX Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, IBRX has a market cap of 2.36B. Regarding current trading prices, ORTX is priced at $16.70, while IBRX trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas IBRX's P/E ratio is -4.68. In terms of profitability, ORTX's ROE is -0.50%, compared to IBRX's ROE of +0.65%. Regarding short-term risk, ORTX is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for ORTX.
ORTX vs LBPH Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, LBPH has a market cap of 2.34B. Regarding current trading prices, ORTX is priced at $16.70, while LBPH trades at $59.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas LBPH's P/E ratio is -26.66. In terms of profitability, ORTX's ROE is -0.50%, compared to LBPH's ROE of -0.33%. Regarding short-term risk, ORTX is more volatile compared to LBPH. This indicates potentially higher risk in terms of short-term price fluctuations for ORTX.
ORTX vs DICE Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, DICE has a market cap of 2.27B. Regarding current trading prices, ORTX is priced at $16.70, while DICE trades at $47.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas DICE's P/E ratio is -21.91. In terms of profitability, ORTX's ROE is -0.50%, compared to DICE's ROE of +0.56%. Regarding short-term risk, ORTX is less volatile compared to DICE. This indicates potentially lower risk in terms of short-term price fluctuations for ORTX.
ORTX vs XENE Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, XENE has a market cap of 2.27B. Regarding current trading prices, ORTX is priced at $16.70, while XENE trades at $29.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas XENE's P/E ratio is -9.82. In terms of profitability, ORTX's ROE is -0.50%, compared to XENE's ROE of -0.32%. Regarding short-term risk, ORTX is less volatile compared to XENE. This indicates potentially lower risk in terms of short-term price fluctuations for ORTX.
ORTX vs MIRM Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, MIRM has a market cap of 2.24B. Regarding current trading prices, ORTX is priced at $16.70, while MIRM trades at $45.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas MIRM's P/E ratio is -28.12. In terms of profitability, ORTX's ROE is -0.50%, compared to MIRM's ROE of -0.34%. Regarding short-term risk, ORTX is less volatile compared to MIRM. This indicates potentially lower risk in terms of short-term price fluctuations for ORTX.
ORTX vs VCYT Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, VCYT has a market cap of 2.23B. Regarding current trading prices, ORTX is priced at $16.70, while VCYT trades at $28.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas VCYT's P/E ratio is 69.49. In terms of profitability, ORTX's ROE is -0.50%, compared to VCYT's ROE of +0.02%. Regarding short-term risk, ORTX is less volatile compared to VCYT. This indicates potentially lower risk in terms of short-term price fluctuations for ORTX.
ORTX vs BLTE Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, BLTE has a market cap of 2.17B. Regarding current trading prices, ORTX is priced at $16.70, while BLTE trades at $67.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas BLTE's P/E ratio is -56.84. In terms of profitability, ORTX's ROE is -0.50%, compared to BLTE's ROE of -0.31%. Regarding short-term risk, ORTX is less volatile compared to BLTE. This indicates potentially lower risk in terms of short-term price fluctuations for ORTX.
ORTX vs CALT Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, CALT has a market cap of 2.15B. Regarding current trading prices, ORTX is priced at $16.70, while CALT trades at $40.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas CALT's P/E ratio is -22.73. In terms of profitability, ORTX's ROE is -0.50%, compared to CALT's ROE of -2.10%. Regarding short-term risk, ORTX is less volatile compared to CALT. This indicates potentially lower risk in terms of short-term price fluctuations for ORTX.
ORTX vs BCRX Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, BCRX has a market cap of 2.14B. Regarding current trading prices, ORTX is priced at $16.70, while BCRX trades at $10.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas BCRX's P/E ratio is -39.27. In terms of profitability, ORTX's ROE is -0.50%, compared to BCRX's ROE of +0.15%. Regarding short-term risk, ORTX is less volatile compared to BCRX. This indicates potentially lower risk in terms of short-term price fluctuations for ORTX.
ORTX vs ARWR Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, ARWR has a market cap of 2.12B. Regarding current trading prices, ORTX is priced at $16.70, while ARWR trades at $15.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas ARWR's P/E ratio is -2.98. In terms of profitability, ORTX's ROE is -0.50%, compared to ARWR's ROE of -0.46%. Regarding short-term risk, ORTX is less volatile compared to ARWR. This indicates potentially lower risk in terms of short-term price fluctuations for ORTX.
ORTX vs NAMSW Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, NAMSW has a market cap of 2.11B. Regarding current trading prices, ORTX is priced at $16.70, while NAMSW trades at $8.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas NAMSW's P/E ratio is N/A. In terms of profitability, ORTX's ROE is -0.50%, compared to NAMSW's ROE of -0.26%. Regarding short-term risk, ORTX is more volatile compared to NAMSW. This indicates potentially higher risk in terms of short-term price fluctuations for ORTX.
ORTX vs NAMS Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, NAMS has a market cap of 2.10B. Regarding current trading prices, ORTX is priced at $16.70, while NAMS trades at $18.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas NAMS's P/E ratio is -10.16. In terms of profitability, ORTX's ROE is -0.50%, compared to NAMS's ROE of -0.26%. Regarding short-term risk, ORTX is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for ORTX.
ORTX vs VCEL Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, VCEL has a market cap of 2.09B. Regarding current trading prices, ORTX is priced at $16.70, while VCEL trades at $41.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas VCEL's P/E ratio is 829.80. In terms of profitability, ORTX's ROE is -0.50%, compared to VCEL's ROE of +0.01%. Regarding short-term risk, ORTX is less volatile compared to VCEL. This indicates potentially lower risk in terms of short-term price fluctuations for ORTX.
ORTX vs DNLI Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, DNLI has a market cap of 2.06B. Regarding current trading prices, ORTX is priced at $16.70, while DNLI trades at $14.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas DNLI's P/E ratio is -5.30. In terms of profitability, ORTX's ROE is -0.50%, compared to DNLI's ROE of -0.36%. Regarding short-term risk, ORTX is less volatile compared to DNLI. This indicates potentially lower risk in terms of short-term price fluctuations for ORTX.
ORTX vs APLS Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, APLS has a market cap of 2.06B. Regarding current trading prices, ORTX is priced at $16.70, while APLS trades at $16.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas APLS's P/E ratio is -9.09. In terms of profitability, ORTX's ROE is -0.50%, compared to APLS's ROE of -1.00%. Regarding short-term risk, ORTX is less volatile compared to APLS. This indicates potentially lower risk in terms of short-term price fluctuations for ORTX.
ORTX vs LGND Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, LGND has a market cap of 2.00B. Regarding current trading prices, ORTX is priced at $16.70, while LGND trades at $103.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas LGND's P/E ratio is -14.19. In terms of profitability, ORTX's ROE is -0.50%, compared to LGND's ROE of -0.16%. Regarding short-term risk, ORTX is less volatile compared to LGND. This indicates potentially lower risk in terms of short-term price fluctuations for ORTX.
ORTX vs HRMY Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, HRMY has a market cap of 1.97B. Regarding current trading prices, ORTX is priced at $16.70, while HRMY trades at $34.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas HRMY's P/E ratio is 13.06. In terms of profitability, ORTX's ROE is -0.50%, compared to HRMY's ROE of +0.24%. Regarding short-term risk, ORTX is less volatile compared to HRMY. This indicates potentially lower risk in terms of short-term price fluctuations for ORTX.
ORTX vs AAPG Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, AAPG has a market cap of 1.96B. Regarding current trading prices, ORTX is priced at $16.70, while AAPG trades at $22.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas AAPG's P/E ratio is -30.48. In terms of profitability, ORTX's ROE is -0.50%, compared to AAPG's ROE of N/A. Regarding short-term risk, ORTX is less volatile compared to AAPG. This indicates potentially lower risk in terms of short-term price fluctuations for ORTX.
ORTX vs KYMR Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, KYMR has a market cap of 1.95B. Regarding current trading prices, ORTX is priced at $16.70, while KYMR trades at $30.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas KYMR's P/E ratio is -9.65. In terms of profitability, ORTX's ROE is -0.50%, compared to KYMR's ROE of -0.30%. Regarding short-term risk, ORTX is less volatile compared to KYMR. This indicates potentially lower risk in terms of short-term price fluctuations for ORTX.
ORTX vs CGON Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, CGON has a market cap of 1.93B. Regarding current trading prices, ORTX is priced at $16.70, while CGON trades at $25.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas CGON's P/E ratio is -17.98. In terms of profitability, ORTX's ROE is -0.50%, compared to CGON's ROE of -0.11%. Regarding short-term risk, ORTX is less volatile compared to CGON. This indicates potentially lower risk in terms of short-term price fluctuations for ORTX.
ORTX vs KNSA Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, KNSA has a market cap of 1.89B. Regarding current trading prices, ORTX is priced at $16.70, while KNSA trades at $25.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas KNSA's P/E ratio is -107.79. In terms of profitability, ORTX's ROE is -0.50%, compared to KNSA's ROE of -0.04%. Regarding short-term risk, ORTX is less volatile compared to KNSA. This indicates potentially lower risk in terms of short-term price fluctuations for ORTX.
ORTX vs TVTX Comparison
ORTX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ORTX stands at 380.11M. In comparison, TVTX has a market cap of 1.88B. Regarding current trading prices, ORTX is priced at $16.70, while TVTX trades at $21.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ORTX currently has a P/E ratio of -4.07, whereas TVTX's P/E ratio is -7.61. In terms of profitability, ORTX's ROE is -0.50%, compared to TVTX's ROE of -11.84%. Regarding short-term risk, ORTX is less volatile compared to TVTX. This indicates potentially lower risk in terms of short-term price fluctuations for ORTX.